Medical Cannabis for Crohn’s Disease and IBD: The Research, the Access and the Reality

Medically reviewed by the Cannamedical Britannia Clinical Team, May 2026

Approximately 300,000 people in the United Kingdom live with inflammatory bowel disease — a figure that encompasses both Crohn’s disease and ulcerative colitis, two conditions that share a propensity for disrupting the digestive tract in profoundly different ways. For most patients, established therapies — biologics, immunomodulators, corticosteroids — offer meaningful disease control. But for a stubborn minority, estimated at around 15 per cent by clinical gastroenterologists, conventional treatment proves insufficient, leaving them to manage debilitating pain, unpredictable flares, chronic nausea and nutritional deficits that erode quality of life over years, sometimes decades. It is within this underserved population that medical cannabis has attracted serious scientific interest — and, increasingly, cautious clinical consideration.

This article examines the current state of the evidence, the mechanisms by which cannabinoids may interact with the inflamed gut, and the practical realities facing IBD patients who seek a prescription in the United Kingdom today.

IBD and the Gut-Endocannabinoid System: The Scientific Mechanism

To understand why cannabis has any plausible role in bowel disease, one must first understand the endocannabinoid system (ECS) — a distributed network of receptors, endogenous ligands and metabolic enzymes that regulates an extraordinary range of physiological processes, from appetite and mood to immune response and gut motility.

The two principal cannabinoid receptors — CB1, found predominantly in the central nervous system and enteric nervous system, and CB2, expressed primarily on immune cells — are both present throughout the gastrointestinal tract. Their natural ligands, anandamide and 2-arachidonoylglycerol (2-AG), modulate intestinal permeability, visceral pain signalling, immune cell activation and the pace of luminal transit. In health, this system operates quietly. In the context of IBD, however, research has consistently demonstrated that the ECS is in a state of dysregulation.

Studies examining colonic biopsy tissue from patients with active Crohn’s and UC have found elevated levels of both CB1 and CB2 receptors in inflamed mucosa compared with non-inflamed tissue — a pattern interpreted by researchers as an attempt by the body to recruit endocannabinoid signalling in response to ongoing inflammation. The implication is consequential: the gut of an IBD patient appears to be reaching for a system that phytocannabinoids — plant-derived compounds including THC and CBD — can directly engage.

Tetrahydrocannabinol (THC) binds to both CB1 and CB2 receptors. At CB1, it reduces the release of pro-inflammatory neuropeptides from enteric neurons and dampens visceral hypersensitivity — the mechanism underlying the abdominal pain and cramping that characterise active IBD. At CB2, THC modulates the behaviour of macrophages and T-cells implicated in mucosal inflammation. Cannabidiol (CBD), which does not bind directly to CB1 or CB2, exerts its effects through a more complex pharmacological profile: it inhibits fatty acid amide hydrolase (FAAH), the enzyme that degrades anandamide, thereby increasing endogenous cannabinoid tone. CBD also acts on TRPV1 channels — involved in pain and inflammation — and on peroxisome proliferator-activated receptor gamma (PPAR-γ), which carries direct anti-inflammatory effects on intestinal epithelial cells.

This dual pharmacology, combining direct receptor agonism with enzyme inhibition and receptor modulation across multiple pathways, makes the cannabis plant a pharmacologically unusual candidate for a disease as mechanistically complex as IBD. Whether that complexity translates to clinical benefit, however, is a question that the evidence answers only partially.

Crohn’s Disease vs Ulcerative Colitis: Different Conditions, Different Evidence

IBD is not a single disease. Crohn’s disease and ulcerative colitis share some features — both are immune-mediated, both cause intestinal inflammation — but they differ fundamentally in their distribution, depth of tissue involvement and, it appears, in their responsiveness to cannabinoid-based interventions.

Ulcerative colitis is confined to the colon and is characterised by continuous, superficial mucosal inflammation beginning at the rectum. Crohn’s disease, by contrast, can affect any part of the gastrointestinal tract from mouth to anus, causes transmural (full-thickness) inflammation, and has a propensity for complications including fistulae, strictures and abscess formation. These anatomical and histological differences matter when evaluating cannabis: CB1 receptor density is highest in the small intestine and colon, regions frequently involved in Crohn’s, and the enteric nervous system — through which cannabis modulates gut motility and pain — is particularly relevant to the transmural inflammation of Crohn’s disease.

The available clinical evidence, while limited in scale, reflects this divergence. Most trials showing symptomatic benefit have enrolled predominantly Crohn’s patients; studies in UC populations have been smaller and their findings less consistent. This is not evidence of inefficacy in colitis — it may simply reflect the trajectory of research funding and patient recruitment. But clinicians prescribing for IBD should not conflate the two conditions when assessing likely benefit.

Clinical Trials and Real-World Data: What Works?

The landmark paper in this field remains the 2011 Israeli trial by Naftali and colleagues, published in the Israel Medical Association Journal, in which 21 patients with treatment-resistant Crohn’s disease received either inhaled cannabis (THC 23%) or placebo over eight weeks. Complete remission — defined by a Crohn’s Disease Activity Index score below 150 — was achieved in 45 per cent of the cannabis group versus 10 per cent of the placebo group. Critically, there was no corresponding reduction in inflammatory markers such as CRP or faecal calprotectin, suggesting that the benefit was predominantly symptomatic rather than disease-modifying at the mucosal level.

A subsequent 2013 trial by the same group, published in Clinical Gastroenterology and Hepatology, examined CBD-rich cannabis oil versus placebo in 20 Crohn’s patients and found no significant difference in remission rates, though CBD patients reported improved quality of life scores — a finding consistent with CBD’s profile as an anxiolytic and analgesic rather than a primary anti-inflammatory in clinical dosing.

The most rigorous evaluation of the evidence base came in 2018, when Irving and colleagues published a systematic review in the BMJ examining randomised controlled trials of cannabinoids across multiple gastrointestinal conditions. Their conclusion was sobering: while cannabis was associated with significant improvements in patient-reported outcomes — pain, nausea, appetite, sleep quality — there was insufficient evidence of endoscopic or histological mucosal healing. The distinction matters enormously in modern IBD management, where treat-to-target strategies demand objective evidence of inflammation control to prevent long-term complications including colorectal cancer.

Real-world observational data, however, presents a more nuanced picture. A 2020 survey of IBD patients using cannabis, published in Inflammatory Bowel Diseases, found that 82 per cent reported symptom improvement, with pain and nausea the most frequently cited benefits. Importantly, 39 per cent reported a reduction in other IBD medications — a figure that, if substantiated in controlled settings, would carry significant health-economic implications. The European Crohn’s and Colitis Organisation (ECCO) has acknowledged this body of evidence in its guidelines, noting that while endoscopic remission has not been demonstrated, symptomatic benefit in refractory patients represents a legitimate clinical endpoint deserving further investigation.

Crohn’s and Cannabis: Managing Pain, Nausea and Appetite

For the approximately 15 per cent of IBD patients who exhaust conventional options, the conversation about cannabis is not primarily about mucosal healing — it is about functional survival. The symptom burden of severe Crohn’s disease includes visceral pain that can be refractory to opioids (which carry their own GI complications), intractable nausea that makes maintaining nutrition impossible, and profound appetite suppression that contributes to the malnutrition seen in up to 85 per cent of hospitalised Crohn’s patients.

In this context, the evidence for cannabis is more compelling. THC’s antiemetic properties are well-established: it was the mechanism behind nabilone (a synthetic cannabinoid) receiving UK marketing authorisation for chemotherapy-induced nausea decades ago. The same CB1-mediated pathway — reducing neurotransmitter release in the emetic reflex centres of the brainstem — applies in IBD-related nausea. For visceral pain, the picture is similarly encouraging: multiple systematic reviews confirm that cannabinoids reduce pain scores across a range of chronic pain conditions, and the concentration of CB1 receptors in the enteric nervous system provides a mechanistically plausible basis for benefit in abdominal pain specifically.

Appetite stimulation, mediated by THC’s action on hypothalamic CB1 receptors, is one of the most documented effects of cannabis and directly addresses a consequence of active IBD that can itself become life-threatening. For patients unable to tolerate standard nutritional supplementation or requiring parenteral nutrition, the option of an appetite-stimulating medication with concurrent analgesic and antiemetic properties is not trivial.

The Microbiome Connection: Emerging Research

Perhaps the most intriguing emerging strand of cannabinoid research in IBD concerns the gut microbiome — the 38 trillion bacteria, fungi and viruses that co-inhabit the human intestinal tract and whose dysbiosis is increasingly recognised as both a feature and a driver of inflammatory bowel disease.

Preclinical research, primarily in murine models of colitis, has demonstrated that both CBD and THC can alter the composition of the gut microbiome in directions that correlate with reduced intestinal inflammation. A 2020 study in the Journal of Crohn’s and Colitis found that CBD administration in a mouse model of DSS-induced colitis increased the relative abundance of Akkermansia muciniphila — a mucin-degrading bacterium associated with intestinal barrier integrity — while reducing populations of pro-inflammatory Proteobacteria. Separately, research has shown that the endocannabinoid system directly regulates gut permeability: CB1 activation tightens intestinal tight junctions, reducing the translocation of luminal bacteria across the mucosal barrier — so-called leaky gut — that amplifies systemic inflammation in active IBD.

These findings remain preclinical. No adequately powered human trial has yet demonstrated cannabis-induced microbiome modification as a mechanism of clinical benefit in IBD. But the convergence of the ECS with microbiome biology represents one of the more scientifically compelling rationales for further investigation, and several trials currently in recruitment — including one at University College London — are examining precisely this question.

How UK Gastroenterologists View Medical Cannabis

British gastroenterology has not, on the whole, embraced medical cannabis with enthusiasm — and for reasons that are more principled than reflexive. The specialty’s commitment to treat-to-target strategies, in which objective mucosal healing is the primary endpoint, sits uncomfortably with a therapy that demonstrably improves symptoms while leaving endoscopic inflammation untouched. The risk, as leading gastroenterologists have articulated, is that cannabis provides symptomatic relief that masks ongoing mucosal disease progression — the precise scenario that leads to long-term complications including strictures, fistulae and colorectal cancer.

Crohn’s and Colitis UK, the leading patient charity, reflects this caution in its official position: it acknowledges patient interest in cannabis, does not dismiss the symptomatic evidence, but declines to recommend it as a treatment and calls for more robust clinical trials before any endorsement. The British Society of Gastroenterology has not issued specific guidance on cannabis prescription for IBD, leaving individual clinicians to navigate the question without institutional framework.

This professional reticence does not mean hostility. Several UK gastroenterologists, particularly those at specialist IBD centres, are now willing to engage with patients about medical cannabis in the context of refractory disease — and some will provide supporting letters to cannabis clinics to facilitate prescribing. The shift has been gradual and driven partly by patient demand, partly by the growing observational evidence base, and partly by the recognition that for patients who have failed multiple biological agents, the risk-benefit calculus changes significantly.

Getting a Prescription for IBD in the UK: Routes and Challenges

Medical cannabis has been legal in the United Kingdom since November 2018, when Schedule 1 of the Misuse of Drugs Regulations was amended to permit specialist medical practitioners to prescribe cannabis-based medicinal products (CBMPs). In practice, prescribing is confined to specialists — not GPs — and requires a clinical justification that conventional treatments have been inadequate.

For IBD patients, the pathway to a prescription involves several steps. The most direct route is referral to one of the specialist medical cannabis clinics now operating across the UK, of which there are several dozen, including Sapphire Medical Clinics, Releaf, Alternaleaf and Rokeby Medical. These clinics employ consultants — typically gastroenterologists, neurologists or pain specialists — who assess whether a patient meets criteria for cannabis prescribing. For IBD, this generally means documented evidence of active disease, a history of inadequate response to at least two conventional therapies (typically including a biologic), and specialist gastroenterology confirmation of diagnosis.

The financial barrier is significant. Medical cannabis is not currently available on NHS prescription for IBD — NICE has not issued guidance supporting this, and NHS England has not commissioned it as a treatment. Patients accessing cannabis via private clinics typically pay between £150 and £300 for an initial consultation, with monthly prescription costs ranging from £100 to £400 depending on product type and dose. For patients already managing the significant indirect costs of chronic IBD, this is prohibitive.

Products available for IBD include full-spectrum cannabis flower (requiring a dry-herb vaporiser), cannabis oils (including CBD-dominant preparations) and — less commonly — standardised oral preparations with defined THC:CBD ratios. The choice of product and route of administration has meaningful pharmacokinetic implications: inhaled cannabis reaches peak plasma concentration within minutes and has a duration of effect of two to four hours; oral preparations have a delayed onset of up to two hours but a substantially longer and more consistent effect profile, which may be preferable for managing the continuous symptoms of active IBD rather than acute flares. You can explore your options in detail through our comprehensive UK guide to medical cannabis and learn about accessing care through our clinician directory.

For clinicians wishing to understand the available formulary and the evidence behind specific cannabis products suitable for IBD prescribing, our For Clinicians hub provides product-level data and clinical reference materials. Patients managing IBD alongside other chronic pain conditions may also find relevant information in our article on medical cannabis for chronic pain in the UK.

Risks: Cannabinoid Hyperemesis Syndrome and GI Complications

Any honest clinical discussion of cannabis in IBD must address the risks — and one risk in particular demands careful attention in a patient population whose primary symptoms include nausea and abdominal pain.

Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition characterised by cyclical vomiting, severe nausea and abdominal cramping in regular, long-term cannabis users. Its pathophysiology remains incompletely understood but likely involves downregulation of CB1 receptors in the gut wall following chronic high-dose THC exposure, resulting in the loss of cannabis’s antiemetic effect and the emergence of a hyperemetic state. The condition resolves only with cessation of cannabis use, and the single clinical identifier — temporary relief with hot bathing or showering — reflects the involvement of TRPV1 thermoregulatory mechanisms.

For IBD patients, CHS presents a diagnostic and therapeutic trap. Cyclical nausea and abdominal pain are features of active IBD flare, and a patient who has been using cannabis therapeutically may develop CHS symptoms that are indistinguishable from worsening disease. Clinicians and patients must maintain a high index of suspicion: if nausea or abdominal symptoms worsen during cannabis treatment rather than improving, CHS must be excluded before escalating IBD therapy.

Beyond CHS, other GI-specific considerations include cannabis’s effect on gut motility. CB1 agonism slows intestinal transit — an effect that may be beneficial for patients with diarrhoea-predominant IBD but is a potential concern in patients with Crohn’s strictures, where delayed transit can precipitate obstruction. High-dose THC can also suppress appetite in some individuals — paradoxically the opposite of its intended effect — through central mechanisms that override peripheral orexigenic signalling.

The cognitive and psychiatric risks of regular THC use are well-documented and apply to IBD patients as to any population: impaired short-term memory, increased anxiety in susceptible individuals, and — with long-term high-dose use — a small but real risk of cannabis use disorder. These considerations must be part of the informed consent process in any clinical prescribing setting. The evidence profile for CBD-dominant preparations, which carry minimal psychoactive risk, is therefore attractive for IBD patients in whom the primary target symptoms are inflammation and pain rather than acute nausea or appetite stimulation.

Conclusion

Medical cannabis occupies a carefully delineated space in the management of IBD in the United Kingdom. It is not a therapy that has demonstrated mucosal healing or disease remission in controlled trials. It has, however, demonstrated consistent symptomatic benefit — in pain, nausea and appetite — in a patient population that frequently exhausts conventional options before finding adequate relief. For the estimated 15 per cent of IBD patients who are inadequately served by existing treatments, that symptomatic benefit is not a minor footnote but a potentially transformative clinical reality.

The scientific rationale, rooted in the gut’s own endocannabinoid system, is robust. The real-world data, while methodologically limited, is consistently positive for patient-reported outcomes. The barriers — financial, regulatory and attitudinal among prescribers — are real but navigable. And the emerging microbiome research, if substantiated in human trials, may yet establish a mechanistic pathway to mucosal benefit that would shift the conversation considerably.

For patients with treatment-refractory Crohn’s disease or ulcerative colitis, the conversation with a specialist is worth having. The evidence may be incomplete, but for those managing daily pain, nausea and appetite loss on inadequate conventional therapy, incomplete evidence evaluated honestly is rather more useful than no conversation at all.

Sources and further reading

• Irving PM et al. Medical cannabis in adults with treatment-resistant Crohn’s disease. BMJ, 2018.
• Naftali T et al. Cannabis induces a clinical response in patients with Crohn’s disease: a prospective placebo-controlled study. Clinical Gastroenterology and Hepatology, 2013.
• Crohn’s and Colitis UK. Position statement on cannabis and IBD. 2022.
• European Crohn’s and Colitis Organisation (ECCO). ECCO Guidelines on Therapeutics in Crohn’s Disease. Journal of Crohn’s and Colitis, 2022.
• Mbabazi E et al. Cannabis and the gut microbiome: modulation of dysbiosis in colitis. Journal of Crohn’s and Colitis, 2020.